All Stories

  1. Global article collection: essential reads from around the world
  2. Systematic Review of Existing Stroke Guidelines: Case for a Change
  3. Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region
  4. How China controls the Covid-19 epidemic through public health expenditure and policy?
  5. Correction to: Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications
  6. Future health spending forecast in leading emerging BRICS markets in 2030: health policy implications
  7. Predictors of loss due to pharmaceutical fraud: evidence from the U.S.
  8. Asian innovation in pharmaceutical and medical device industry – beyond tomorrow
  9. The Global South political economy of health financing and spending landscape – history and presence
  10. Therapeutic innovations: the future of health economics and outcomes research – increasing role of the Asia-Pacific
  11. A Proactive Approach to Identify the Exposure Risk to COVID-19: Validation of the Pandemic Risk Exposure Measurement (PREM) Model Using Real-World Data
  12. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
  13. Sustainability Challenge of Eastern Europe—Historical Legacy, Belt and Road Initiative, Population Aging and Migration
  14. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India’s Role at the WTO Platform
  15. Sustainability Challenge of Eastern Europe - Historical Legacy, Belt and Road Initiative, Population Ageing and Migration
  16. Predictors of Loss Due to Pharmaceutical Fraud: Evidence From the U.S.
  17. Future Health Spending Forecast in Leading Emerging BRICS Markets in 2030 - Health Policy Implications
  18. Happiness: A Novel Outcome Measure in Stroke?
  19. Current utilisation patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
  20. The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
  21. Editorial: NCDs – Core Challenge of Modern Day Health Care Establishments
  22. Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead
  23. Editorial: Accelerated Globalization and Its Impact to the World's Health Care Achievement
  24. Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study
  25. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  26. Forecasted Incidence, Intensive Care Unit Admissions and Projected Mortality Attributable to Covid-19 in Portugal, UK, Germany, Italy and France – 4 Weeks Ahead
  27. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  28. Highlighting the Role of Universally Available and Innate Immune Cell Counts in Acute Ischemic Stroke: A Scoping Review
  29. Public Health Policy of India and COVID-19: Diagnosis and Prognosis of the Combating Response
  30. Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country
  31. Elevated Neutrophil to Lymphocyte Ratio Predicts In-hospital Mortality Among Stroke Patients in a Metropolitan hospital in Australia, Universal Value-added measure in Stroke Care
  32. Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change<strong> </strong>
  33. Scoping Review of Existing Stroke Guidelines; Argument for a Value-Added Change
  34. Demographic forecasting of population aging in Greece and Cyprus: one big challenge for the Mediterranean health and social system long-term sustainability
  35. Universally Available Innate and Adaptive Immune Cell Counts in Acute Ischemic Stroke (AIS) in the Context of Shared Pathobiology with COVID-19; Scoping Review
  36. Sanitary and Hygienic Aspects of the COVID-19 Self-isolation
  37. Mapping routine measles vaccination in low- and middle-income countries
  38. Corona-Triggered Global Macroeconomic Crisis of the Early 2020s
  39. Organizational measures aiming to combat COVID-19 in the Russian Federation: the first experience
  40. Five insights from the Global Burden of Disease Study 2019
  41. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  42. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  43. <p>A Country Pandemic Risk Exposure Measurement Model</p>
  44. <p>Predictors of (in)efficiencies of Healthcare Expenditure Among the Leading Asian Economies – Comparison of OECD and Non-OECD Nations</p>
  45. Gross Domestic Product and Health Expenditure Growth in Balkan and East European Countries—Three-Decade Horizon
  46. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
  47. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
  48. Fraudster’s and victims’ profiles and loss predictors’ hierarchy in the mental healthcare industry in the US
  49. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17
  50. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  51. Real GDP growth rates and healthcare spending – comparison between the G7 and the EM7 countries
  52. Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  53. Promises and Hurdles of Medical Tourism Development in the Russian Federation
  54. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  55. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  56. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  57. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  58. Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow
  59. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  60. Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017
  61. A Correlation Study of the Colorectal Cancer Statistics and Economic Indicators in Selected Balkan Countries
  62. Alcohol Consumption among the Elderly Citizens in Hungary and Serbia—Comparative Assessment
  63. GBD 2016. Occupational Carcinogens Collaborators
  64. Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  65. Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  66. The Evaluation of Antibiotic Consumption at the Inpatient Level in Kazakhstan from 2011 to 2018
  67. Structural Factors Responsible for Universal Health Coverage in Low- and Middle-Income Countries: Results From 118 Countries
  68. Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
  69. Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017
  70. Real GDP growth rates and health care spending – Comparison between the G7 and the EM7 countries
  71. Mapping child growth failure across low- and middle-income countries
  72. Mapping disparities in education across low- and middle-income countries
  73. Dynamics of Health Care Financing and Spending in Serbia in the XXI Century
  74. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  75. The Impact of the Socio-Demographic Characteristics of Complementary and Alternative Medicine Users in Serbia on OTC Drug Consumption
  76. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
  77. Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review
  78. The impact of health expenditures on public health in BRICS nations
  79. Underlying Differences in Health Spending Within the World Health Organisation Europe Region—Comparing EU15, EU Post-2004, CIS, EU Candidate, and CARINFONET Countries
  80. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050
  81. Analysis of the Financing of Russian Health Care over the Past 100 Years
  82. Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report
  83. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  84. Comparative financing analysis and political economy of noncommunicable diseases
  85. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016
  86. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  87. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  88. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  89. Editorial: Challenges of Pharmacoeconomics in Global Health Arena
  90. Editorial: Global Population Aging - Health Care, Social and Economic Consequences
  91. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  92. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  93. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  94. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  95. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  96. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  97. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  98. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  99. Department of Error
  100. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016
  101. The Influence of Universal Health Coverage on Life Expectancy at Birth (LEAB) and Healthy Life Expectancy (HALE): A Multi-Country Cross-Sectional Study
  102. Global Burden of Multiple Myeloma
  103. Global Mortality From Firearms, 1990-2016
  104. Cold War Legacy in Public and Private Health Spending in Europe
  105. High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary
  106. Antibiotic Resistance in Syria: A Local Problem Turns Into a Global Threat
  107. Alcohol use and attributable disease burden in 195
  108. The burden of disease in Greece, health loss, risk factors, and health financing, 2000–16: an analysis of the Global Burden of Disease Study 2016
  109. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  110. Access to orphan drugs – comparison across Balkan countries
  111. High Out-of-Pocket Health Spending in Countries With a Mediterranean Connection
  112. Population aging and migration – history and UN forecasts in the EU-28 and its east and south near neighborhood – one century perspective 1950–2050
  113. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria
  114. Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  115. Transposition and implementation of EU rare disease policy in Eastern Europe
  116. Department of Error
  117. Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies
  118. RESILIENCE, PSYCHIATRY AND RELIGION FROM PUBLIC AND GLOBAL MENTAL HEALTH PERSPECTIVE Dialogue and Cooperation in the Search for Humanistic Self, Compassionate Society and Empathic Civilization
  119. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
  120. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
  121. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  122. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  123. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  124. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
  125. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  126. Department of Error
  127. Growth of Global Publishing Output of Health Economics in the Twenty-First Century: A Bibliographic Insight
  128. Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study
  129. The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study
  130. Burden of cancer in the Eastern Mediterranean Region, 2005–2015: findings from the Global Burden of Disease 2015 Study
  131. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
  132. Pharmaceutical expenditure dynamics in the Balkan countries
  133. Child and Adolescent Health From 1990 to 2015
  134. Alcohol Beverage Household Expenditure, Taxation and Government Revenues in Broader European WHO Region
  135. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  136. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  137. Disability, Work Absenteeism, Sickness Benefits, and Cancer in Selected European OECD Countries—Forecasts to 2020
  138. Satisfaction with Health Services among the Citizens of Serbia
  139. Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia
  140. Within the triangle of healthcare legacies: comparing the performance of South-Eastern European health systems
  141. Population ageing alongside health care spending growth
  142. Department of Error
  143. Global, Regional, and National Levels of Maternal Mortality, 1990–2015
  144. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
  145. Caffeine consumption patterns and determinants among adolescents in Serbia
  146. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  147. Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  148. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  149. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015
  150. Direct Medical Costs Of Treating Colorectal Cancer Patients With Different Chemotherapy Protocols Regarding Stage And Outcome Of The Disease
  151. Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025
  152. Capitation-Based Financing Hampers the Provision of Preventive Services in Primary Health Care
  153. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015
  154. Correction to Lancet HIV 2016; 3: e361–87
  155. Commentary: Implementing Pro-Poor Universal Health Coverage
  156. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015
  157. Health Economics at the Crossroads of Centuries – From the Past to the Future
  158. Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey
  159. Review of Diagnosis-Related Group-Based Financing of Hospital Care
  160. Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly
  161. Long Term Dental Work Force Build-Up and DMFT-12 Improvement in the European Region
  162. Growth of Global Health Spending Share in Low and Middle Income Countries
  163. Do Health Reforms Impact Cost Consciousness of Health Care Professionals? Results from a Nation-Wide Survey in the Balkans
  164. The New and Old Europe: East-West Split in Pharmaceutical Spending
  165. Editorial: Health Care Financing and Affordability in the Emerging Global Markets
  166. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy
  167. Health Care Financing and Affordability in the Emerging Global Markets
  168. The aging of Europe. The unexplored potential
  169. Life expectancy and health expenditure evolution in Eastern Europe—DiD and DEA analysis
  170. Comparison of historical medical spending patterns among the BRICS and G7
  171. Regulatory Issues Surrounding Audit of Electronic Cigarette Charge Composition
  172. When cure becomes an illness—abuse of addictive prescription medicines
  173. Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
  174. Improvements in Neonatal and Childhood Medical Care – Perspective from the Balkans
  175. Five-year survival and costs of care in metastatic colorectal cancer: conventional versus monoclonal antibody-based treatment protocols
  176. BRIC’s Growing Share of Global Health Spending and Their Diverging Pathways
  177. Growing Burden of Non-Communicable Diseases in the Emerging Health Markets: The Case of BRICS
  178. Hospital oncology costs among the cohort of elderly in an aging South-Eastern European nation
  179. Cost differentials of dental outpatient care across clinical dentistry branches
  180. Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity,
  181. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition
  182. Accessibility and Affordability of Alcohol Dependency Medical Care in Serbia
  183. Can Didactic Continuing Education Improve Clinical Decision Making and Reduce Cost of Quality? Evidence From a Case Study
  184. Macroeconomic Policy Impact On Oncology-Related Public Expenditure In An Emerging European Market – Signs Of Early Recovery
  185. Structural validity and reliability of the healthcare professionals' economic reasoning questionnaire
  186. End-of-life costs of medical care for advanced stage cancer patients
  187. Health Financing Constrained by Population Aging - An Opportunity to Learn from Japanese Experience / Finansiranje Zdravstvene Zaštite U Uslovima Starenja Popualcije - Prilika Da Učimo Na Japanskom Iskustvu
  188. LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study
  189. Intentional Self-Poisonings and Unintentional Poisonings of Adolescents With Nonfatal Outcomes
  190. Cost Comparison Among First Line Monoclonal Antibodies-Based Oncology Treatment Protocols
  191. Costs of Dental Outpatient Care – Resource Use Differentials Across Clinical Dentistry Branches
  192. 10th World IHEA and ECHE joint congress: Health Economics in the Age of Longevity
  193. Radiation therapy remains the key cost driver of oncology inpatient treatment
  194. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
  195. Contemporary generic market in Japan – key conditions to successful evolution
  196. Health expenditure dynamics in Serbia 1995-2012
  197. 10.5937/mckg48-5071 = Recent developments in the world's leading generic markets
  198. The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care
  199. The key role of the leading emerging BRIC markets in the future of global health care
  200. Radiology Services Costs and Utilization Patterns Estimates in Southeastern Europe—A Retrospective Analysis from Serbia
  201. Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia
  202. Cross-sectional survey on complementary and alternative medicine awareness among health care professionals and students using CHBQ questionnaire in a Balkan country
  203. Craniocerebral injuries in traffic accidents with fatal outcomes
  204. Assessment of Viral Genotype Impact to the Cost-Effectiveness and Overall Costs of Care for Peg-Interferon-2α + Ribavirine Treated Chronic Hepatitis C Patients
  205. FARMAKOLOŠKI IN VITRO MODELI ZA PREDKLINIČKO ISPITIVANJE LEKOVA - PRIMER hSERT TRANSFICIRANIH HUMANIH EMBRIONALNIH ĆELIJA BUBREGA
  206. Serbian and Austrian Alcohol-Dependent Patients: A Comparison of Two Samples Regarding Therapeutically Relevant Clinical Features
  207. Resource allocation strategies in Southeastern European health policy
  208. Validation of a patient satisfaction questionnaire in primary health care
  209. Role of anticonvulsant therapeutic drug monitoring in improving clinical outcomes: An example of 12 adult epilepsy patients
  210. Estimate of clinical outcomes from the patient perspective is important for clinical decision making
  211. Blood alcohol concentration impact on the traffic accident rates with fatal outcome
  212. Analysis of toxicity and tolerance of contrast agents in conventional, CT and MR
  213. Inpatient Detoxification Procedure and Facilities: Financing Considerations from an Eastern European Perspective
  214. Current efforts and proposals to reduce healthcare costs in Serbia
  215. Economics of cancer related medical care: Worldwide estimates and available domestic evidence
  216. A Nonlinear Mixed Effects Modelling Analysis of Topiramate Pharmacokinetics in Patients with Epilepsy
  217. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia
  218. Current clinical evidence on topiramate pharmacokinetics
  219. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy
  220. Cost-Effectiveness of Ritodrine and Fenoterol for Treatment of Preterm Labor in a Low–Middle-Income Country: A Case Study
  221. Effect of exogenous glutamate and N-Methyl-D-aspartic acid on spontaneous activity of isolated human ureter
  222. Inhibitory effects of selected antiepileptics on spontaneous motility of isolated human oviducts